Cord blood transplantation for AML: Comparable LFS in patients with de novo versus secondary AML in CR1, an ALWP/EBMT study
British Journal of Haematology · 2024
DOI: 10.1111/bjh.19130 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Haematology, 2024. Verfasst von Frédéric Baron und 23 weiteren Autor:innen. Beteiligte Einrichtung: GIGA-I3, Université de Liège et CHU de Liège, Liège, Belgium. Hauptthemen laut MEDLINE: Cord Blood Stem Cell Transplantation, Leukemia, Myeloid, Acute, Hematopoietic Stem Cell Transplantation, Neoplasms, Second Primary. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 32 Literaturangaben. Gefördert von: Fonds De La Recherche Scientifique - FNRS.
Abstract (Originalsprache)
We investigated whether secondary versus de novo acute myeloid leukaemia (AML) would be associated with poor outcomes in adult acute AML patients in first complete remission (CR1) receiving unrelated cord blood transplantation (CBT). This is a retrospective study from the acute leukaemia working party of the European Society for Blood and Marrow Transplantation. Inclusion criteria included adult at first allogeneic haematopoietic cell transplantation between 2000 and 2021, unrelated single or double unit CBT, AML in CR1, no ex vivo T‐cell depletion and no post‐transplant cyclophosphamide. The primary end‐point of the study was leukaemia‐free survival (LFS). A total of 879 patients with de novo ( n = 696) or secondary ( n = 183) AML met the inclusion criteria. In multivariable analyses, sAML patients had non‐significantly different LFS (HR = 0.98, p = 0.86), overall survival (HR = 1.07, p = 0.58), relapse incidence (HR = 0.74, p = 0.09) and non‐relapse mortality (HR = 1.26, p = 0.13) than those with de novo AML. Our results demonstrate non‐significantly different LFS following CBT in adult patients with secondary versus de novo AML.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- GIGA-I3, Université de Liège et CHU de Liège, Liège, Belgium.
- Division of Hematology and Bone Marrow Transplantation, The Chaim Sheba Medical Center, Ramat-Gan, Israel.
- EBMT Statistical Unit, Paris, France.
- Department of Hematology, Saint Antoine Hospital, Paris, France.
- INSERM UMR 938, Paris, France.
- Sorbonne University, Paris, France.
ORCID-Profile: Frédéric Baron, Arnon Nagler, Edouard Forcade, Patrice Chevallier, Annalisa Ruggeri, Mohamad Mohty, Fabio Ciceri
Förderung
- Fonds De La Recherche Scientifique - FNRS
Zitieren
APA
Baron, F., Nagler, A., Galimard, J. E., Sanz, J., Versluis, J., Forcade, E., Chevallier, P., Sirvent, A., Anthias, C., Kuball, J., Furst, S., Rambaldi, A., Sierra, J., von dem Borne, P. A., Gallego Hernanz, M. P., Cluzeau, T., Robinson, S., Raiola, A. M., Labussière-Wallet, H., …, & Ciceri, F. (2024). Cord blood transplantation for AML: Comparable LFS in patients with de novo versus secondary AML in CR1, an ALWP/EBMT study. British Journal of Haematology. https://doi.org/10.1111/bjh.19130
Vancouver
Baron F, Nagler A, Galimard JE, Sanz J, Versluis J, Forcade E, et al. Cord blood transplantation for AML: Comparable LFS in patients with de novo versus secondary AML in CR1, an ALWP/EBMT study. British Journal of Haematology. 2024. doi:10.1111/bjh.19130
BibTeX
@article{Baron2024,
author = {Baron, Frédéric and Nagler, Arnon and Galimard, Jacques-Emmanuel and Sanz, Jaime and Versluis, Jurjen and Forcade, Edouard and Chevallier, Patrice and Sirvent, Anne and Anthias, Chloe and Kuball, Jürgen and Furst, Sabine and Rambaldi, Alessandro and Sierra, Jorge and von dem Borne, Peter A and Gallego Hernanz, Maria Pilar and Cluzeau, Thomas and Robinson, Stephen and Raiola, Anna Maria and Labussière-Wallet, Hélène and Byrne, Jenny L and Malfuson, Jean-Valère and Ruggeri, Annalisa and Mohty, Mohamad and Ciceri, Fabio},
title = {Cord blood transplantation for AML: Comparable LFS in patients with de novo versus secondary AML in CR1, an ALWP/EBMT study},
journal = {British Journal of Haematology},
year = {2024},
doi = {10.1111/bjh.19130}
}
EUVIMED